Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update

Chimerix, Inc. (NASDAQ:CMRX) was the recipient of a large decrease in short interest in March. As of March 15th, there was short interest totalling 3,410,000 shares, a decrease of 27.9% from the February 28th total of 4,730,000 shares. Based on an average daily volume of 3,850,000 shares, the short-interest ratio is currently 0.9 days. Approximately 4.3% of the shares of the company are sold short.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Jefferies Financial Group reiterated a “hold” rating and issued a $8.50 price target (down from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th. HC Wainwright reiterated a “neutral” rating and set a $8.55 price objective (down previously from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Wedbush restated a “neutral” rating and set a $8.55 target price (up previously from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th. Finally, StockNews.com began coverage on shares of Chimerix in a report on Sunday, March 23rd. They issued a “hold” rating on the stock.

Insider Buying and Selling

In related news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last three months, insiders have sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Bender Robert & Associates bought a new stake in Chimerix during the fourth quarter worth approximately $37,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Chimerix in the 4th quarter valued at approximately $59,000. Jane Street Group LLC purchased a new position in shares of Chimerix in the 4th quarter worth approximately $62,000. Diadema Partners LP bought a new position in shares of Chimerix during the 4th quarter valued at approximately $101,000. Finally, Squarepoint Ops LLC purchased a new stake in Chimerix during the 4th quarter valued at $130,000. Institutional investors own 45.42% of the company’s stock.

Chimerix Price Performance

NASDAQ:CMRX remained flat at $8.50 during trading hours on Friday. The company’s stock had a trading volume of 835,696 shares, compared to its average volume of 2,130,045. The company has a market capitalization of $797.33 million, a PE ratio of -9.04 and a beta of 0.32. Chimerix has a 1-year low of $0.75 and a 1-year high of $8.53. The company’s 50 day moving average price is $5.84 and its 200 day moving average price is $3.11.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. The business had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.31 million. Sell-side analysts anticipate that Chimerix will post -0.99 EPS for the current fiscal year.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.